ExpreS2ion Biotech Holding
1.66 SEK
0.00 %
Less than 1K followers
EXPRS2
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
0.00 %
-25.45 %
-69.56 %
-70.86 %
-69.87 %
-79.99 %
-96.87 %
-99.63 %
-97.02 %
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read moreMarket cap
39.3M SEK
Turnover
132.91K SEK
Revenue
3.66M
EBIT %
-1,210.56 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 2026-05-29
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
25/6
2026
General meeting '26
20/8
2026
Interim report Q2'26
12/11
2026
Interim report Q3'26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
ExpreS2ion: Presentation of Q1 2026 report (Recording)
ExpreS2ion Biotech – Presentation of Q1 2026 Interim Report
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools